These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23989317)

  • 1. Polypill for cardiovascular disease prevention--reply.
    Smith R; McCready T; Yusuf S
    JAMA; 2013 Aug; 310(7):749-50. PubMed ID: 23989317
    [No Abstract]   [Full Text] [Related]  

  • 2. Polypill for cardiovascular disease prevention.
    Dalton AR
    JAMA; 2013 Aug; 310(7):749. PubMed ID: 23989135
    [No Abstract]   [Full Text] [Related]  

  • 3. The Polypill in the prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
    [No Abstract]   [Full Text] [Related]  

  • 4. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
    Chao J; Bansilal S
    Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
    [No Abstract]   [Full Text] [Related]  

  • 6. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
    Joshi SR
    J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
    [No Abstract]   [Full Text] [Related]  

  • 8. Improving cardiovascular protection: focus on a cardiovascular polypill.
    Barrios V; Escobar C
    Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy to prevent cardiovascular disease: slow progress.
    Smith R; McCready T; Yusuf S
    JAMA; 2013 Apr; 309(15):1595-6. PubMed ID: 23529576
    [No Abstract]   [Full Text] [Related]  

  • 10. Aspirin in the prevention of cancer.
    Wald NJ; Morris JK; Law MR
    Lancet; 2011 May; 377(9778):1649; author reply 1651-2. PubMed ID: 21571138
    [No Abstract]   [Full Text] [Related]  

  • 11. [The Polypill - A Practicable Approach?].
    Thürmann PA; Kleinerüschkamp AG; Boehme P
    Dtsch Med Wochenschr; 2019 Jun; 144(11):715-718. PubMed ID: 31163467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.
    Hedner T; Kjeldsen SE; Narkiewicz K; Oparil S
    Blood Press; 2016 Oct; 25(5):276-9. PubMed ID: 27071504
    [No Abstract]   [Full Text] [Related]  

  • 14. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular polypill: time to rethink?
    Bondugulapati LN
    Curr Opin Lipidol; 2016 Oct; 27(5):537-8. PubMed ID: 27579548
    [No Abstract]   [Full Text] [Related]  

  • 18. The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence.
    Webster R; Grobbee D; Rodgers A
    Eur J Prev Cardiol; 2020 Mar; 27(4):437-440. PubMed ID: 31446790
    [No Abstract]   [Full Text] [Related]  

  • 19. Polypill in cardiovascular disease: has it's time come?
    Kuppuswamy V; Choo WK; Gupta S
    Indian Heart J; 2009; 61(4):322-7. PubMed ID: 20635733
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
    Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
    Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.